23.04.2015
WILEX AG DE000A11QVV0
DGAP-News: WILEX AG: Results of Heidelberg Pharma's research cooperation with MD Anderson Cancer Center published in Nature journal
DGAP-News: WILEX AG / Key word(s): Study results
WILEX AG: Results of Heidelberg Pharma's research cooperation with MD
Anderson Cancer Center published in Nature journal
23.04.2015 / 09:15
---------------------------------------------------------------------
PRESS RELEASE
Results of Heidelberg Pharma's research cooperation with MD Anderson Cancer
Center published in Nature journal
- Subpopulation of colorectal cancers (CRC) is more vulnerable for
therapy by ATACs because of a common genetic alteration
- Responsible for high subpopulation sensitivity is a hemizygous status
of TP53 tumor suppressor gene and POLR2A gene, occuring in about 50% of
CRC patients
- Patient stratification by gene status of TP53 or POLR2A could expand
therapeutic window of ATACs significantly
Munich, Germany, 23 April 2015 - WILEX AG (ISIN DE000A11QVV0 / WL6 / FSE)
today announced that pioneering study results on the Antibody Targeted
Amanitin Conjugates (ATACs) technology have been published in the
peer-reviewed journal Nature, in a report by the Department of Cancer
Biology, University of Texas MD Anderson Cancer Center and scientists of
Heidelberg Pharma, a subsidiary of WILEX.
In preclinical studies, research groups from MD Anderson and Heidelberg
Pharma demonstrated the extraordinary efficacy of ATAC therapeutics in the
treatment of a colorectal cancer subpopulation with alterations in the
status of the tumor suppressor gene TP53. The reason for these alterations
is the co-deletion of one copy of TP53 and the neighbouring POLR2A gene,
which codes for the ATAC-target RNA polymerase II. Such hemizygous gene
status of TP53 and POLR2A leads to reduced expression of RNA polymerase II
and thus the significantly higher sensitivity of cancer cells towards
ATACs. In preclinical, in vitro and in vivo, studies ATACs exhibited an
approximately ten times higher antitumoral activity on POLR2A hemizygous
cancers compared to homozygous cancers. Initial data indicates similar gene
status alterations in other tumors, making ATACs a promising therapeutic
strategy for patients suffering from highly resistant malignancies. In a
clinical setting the selection of patients based on TP53 or POLR2A gene
status will allow the expansion of the therapeutic window of ATACs and
ensure high efficacy while minimizing toxicity.
Professor Andreas Pahl, CSO of Heidelberg Pharma GmbH, commented: "The use
of TP53 and POLR2A gene status as a biomarker for ATAC sensitivity could
allow the stratification of patients most likely to benefit from treatment
with ATACs. Patient selection with respect to payload sensitivity is a new
approach in the field of antibody-drug conjugates (ADCs) and could help to
circumvent the current limitations of this class of therapeutics."
Professor Xiongbin Lu, MD Anderson Cancer Center, said: "Today CRC patients
with altered TP53 gene status have a non-favourable prognosis and only a
few beneficial treatment options. With the discovery of POLR2A as a
therapeutic target for p53 mutant tumors, ATACs could significantly improve
the therapeutic outcome in such cancer populations."
The report abstract can be accessed at nature.com.
About Heidelberg Pharma's proprietary ATAC technology
Antibody-drug conjugates (ADCs) combine the high affinity and specificity
of antibodies with the potential of small cytotoxic molecules for the
treatment of cancer and inflammatory diseases. ATACs are ADCs based on
highly potent amatoxin payloads. Amatoxins are small bicyclic peptides
naturally occurring in the Green Death Cap mushroom. Mode of action of
amatoxins is the inhibition of mRNA transcription by binding to RNA
polymerase II, a mechanism that is crucial for the survival of eukaryotic
cells. Accordingly, ATACs exhibit comparable activity against proliferating
and resting tumor cells. This proliferation independent activity
differentiates ATACs from other ADCs, which preferentially target
proliferating tumor cells. As an additional advantage ATACs could offer a
substantial capability to overcome the resistance mechanisms that might
limit the efficacy of other antibody drug conjugates.
About WILEX and Heidelberg Pharma
WILEX AG is a biopharmaceutical company which has a ready for partnering
portfolio of antibody-based diagnostic and therapeutic Phase III product
candidates for the detection and targeted treatment of clear cell renal
cell carcinoma. Research and development focus on the operations of its
subsidiary Heidelberg Pharma GmbH in Ladenburg, which primarily advances
the development of the innovative platform technology for antibody drug
conjugates (ADC technology) and provides pre-clinical drug discovery and
development services. WILEX is listed at the Frankfurt Stock Exchange: ISIN
DE000A11QVV0 / Symbol WL6. More information is available at www.wilex.com.
Contact IR/PR support WILEX AG MC Services AG Sylvia Wimmer Katja Arnold (CIRO) Corporate Communications Executive Director Tel.: +49 (0)89-41 31 38-29 Tel.: +49 (0)89-210 228-40 Email: investors[at]wilex.com Mobile: +49 (0)160 9360 3022 Grillparzerstr. 10, 81675 Munich, Email: katja.arnold[at]mc- Germany services.eu Business Development Heidelberg Pharma GmbH Dr. Marcel Linssen CBO, Executive Vice President Tel.: +49 (0)6203-1009-40 Email: m.linssen[at]hdpharma.comThis communication contains certain forward-looking statements relating to the Company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "will", "should", "future", "potential" or similar expressions or by a general discussion of the Company's strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial position, earnings, achievements, or industry results, to be materially different from any future results, earnings or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward- looking statements to reflect future events or developments. --------------------------------------------------------------------- 23.04.2015 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: WILEX AG Grillparzerstr. 10 81675 München Germany Phone: +49 (0)89 41 31 38 - 0 Fax: +49 (0)89 41 31 38 - 99 E-mail: [email protected] Internet: www.wilex.com ISIN: DE000A11QVV0 WKN: A11QVV Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart End of News DGAP News-Service --------------------------------------------------------------------- 347549 23.04.2015
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
WILEX AG ISIN: DE000A11QVV0 können Sie bei EQS abrufen
Biotechnologie , A11QVV , HPHA , XETR:WL6